Abstract
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Current Drug Therapy
Title: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Volume: 6 Issue: 4
Author(s): Rajashree Hirlekar, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Abstract: Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Garse Harshal and Kadam Vilasrao, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review, Current Drug Therapy 2011; 6 (4) . https://dx.doi.org/10.2174/157488511798109637
DOI https://dx.doi.org/10.2174/157488511798109637 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Current Medicinal Chemistry Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Current status of Immunotherapy in B Cell Malignancies
Current Drug Targets Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Intracellular ROS Generation Mediates Maleimide-induced Cytotoxicity in Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Tumour Reactions to Hypoxia
Current Molecular Medicine The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia
Current Molecular Medicine Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Peptides as Drugs: From Screening to Application
Current Pharmaceutical Biotechnology